Author: Newsdesk

Posted on

Leading Protection for Cloud-based Applications from Trend Micro

Cloud native security solution protects modern applications and APIs against top threats

PR Newswire

DALLAS, Nov. 23, 2020 /PRNewswire/ — Trend Micro Incorporated (TYO: 4704; TSE: 4704), the leader in cloud security, today announced the availability of its Trend Micro Cloud One™ – Application Security, a cloud native security solution for modern applications and APIs. Delivered as part of its industry-leading platform, Cloud One – Application Security provides code-level visibility and protection against the latest cyber threats.

To learn more about Trend Micro Cloud One – Application Security, please visit: https://www.trendmicro.com/en_us/business/products/hybrid-cloud/cloud-one-application-security.html.

According to a recent Gartner report, “More than 50% of global enterprises will have deployed serverless function platform as a service (fPaaS) by 2025, up from less than 20% today.1” Anticipating this market growth, Cloud One – Application Security offers embedded security for runtime protection to help businesses ensure their data is protected in newly adopted environments.

“Application Security is an invaluable part of the Cloud One platform, integrating technology to provide superior protection for customers deploying applications wherever it makes the most sense for them,” said Wendy Moore, vice president of product marketing for Trend Micro. “Whether building applications on-premises, as a container in the cloud, or using serverless designs, security tools shouldn’t interfere with the development pipeline. With Application Security, businesses can deploy advanced protection across legacy and modern frameworks and languages with ease.”

The critical need for securing cloud applications is highlighted in a recent study from Trend Micro Research. The research identified the top threats targeting serverless applications, which include theft of credentials, sensitive data and code. These and all application layer attacks are commonplace cybersecurity threats being leveraged against a new attack surface.

Cloud One – Application Security not only stops runtime attacks before they occur, it also helps developers pinpoint vulnerabilities in their code that the attack could exploit. Whether applications are developed in-house or by a third party, code identification helps teams prioritize their response and take effective next steps to resolve security issues.

Using Trend Micro’s Cloud One platform, teams can implement a range of security services and compliance checks alongside Application Security without hindering agile cloud development and deployment.

About
 Trend Micro
Trend Micro, a global leader in cybersecurity, helps make the world safe for exchanging digital information. Leveraging over 30 years of security expertise, global threat research, and continuous innovation, Trend Micro enables resilience for businesses, governments, and consumers with connected solutions across cloud workloads, endpoints, email, IIoT, and networks. Our XGen™ security strategy powers our solutions with a cross-generational blend of threat-defense techniques that are optimized for key environments and leverage shared threat intelligence for better, faster protection. With over 6,700 employees in 65 countries, and the world’s most advanced global threat research and intelligence, Trend Micro enables organizations to secure their connected world. www.trendmicro.com.

1 Gartner, A CIO’s Guide to Serverless Computing, Arun Chandrasekaran, Craig Lowery, 28 April 2020

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/leading-protection-for-cloud-based-applications-from-trend-micro-301178330.html

SOURCE Trend Micro Incorporated

Posted on

Lumen and Zoom combine technology and collaboration platforms to deliver an amazing experience

PR Newswire

DENVER, Nov. 23, 2020 /PRNewswire/ — At a time when the world needs to be closer while being apart, Lumen Technologies (NYSE: LUMN) and Zoom have been bringing together their technology capabilities and communications expertise to help businesses keep their vital conversations going. Today, they are expanding that partnership and offering customers Zoom delivered by Lumen. This solution provides an enhanced collaboration experience for businesses around the world, combining the speed and reliability of the Lumen platform with Zoom’s world-class collaboration solutions.

“When the world turned to virtual meetings, Zoom turned to Lumen’s fiber network to power its best-in-class video communications platform,” said Shaun Andrews, chief marketing officer at Lumen. “We’re happy to take this partnership a step further by combining our platforms and our strengths to create Zoom delivered by Lumen. Together, we will help keep families, businesses, schools and hospitals securely connected to the world, and thriving in the 4th industrial revolution.”

Zoom delivered by Lumen brings together Lumen’s embedded network security capabilities with Zoom’s built-in security features to proactively protect businesses using their combined services.

“Lumen has been a very valuable partner to Zoom and over the past several months, we’ve helped businesses connect and grow,” said Ryan Azus, chief revenue officer at Zoom. “With their wide market incumbency, as well deep expertise in the networking and Unified Communications & Collaborations space, Zoom delivered by Lumen is poised to bring our mutual clients an optimal experience that we are very excited about.”

The partnership was first announced in September 2020, with the goal to provide unparalleled managed services and experiences to today’s businesses. Zoom delivered by Lumen will rollout new service features and enhancements over the coming months, including Zoom Phone and Lumen Cloud Connect for Zoom.

About Lumen
Lumen is guided by our belief that humanity is at its best when technology advances the way we live and work. With approximately 450,000 route fiber miles and serving customers in more than 60 countries, we deliver the fastest, most secure platform for applications and data to help businesses, government and communities deliver amazing experiences.

Learn more about the Lumen network, edge cloud, security, communication and collaboration solutions and our purpose to further human progress through technology at news.lumen.com, LinkedIn: /lumentechnologies, Twitter: @lumentechco, Facebook: /lumentechnologies, Instagram: @lumentechnologies and YouTube: /lumentechnologies. Lumen and Lumen Technologies are registered trademarks of Lumen Technologies, LLC in the United States. Lumen Technologies, LLC is a wholly owned affiliate of CenturyLink, Inc. 

* The Lumen brand was launched on September 14, 2020. As a result, CenturyLink, Inc. is referred to as Lumen Technologies, or simply Lumen. The legal name CenturyLink, Inc. is expected to be formally changed to Lumen Technologies, Inc. upon the completion of all applicable requirements.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lumen-and-zoom-combine-technology-and-collaboration-platforms-to-deliver-an-amazing-experience-301178304.html

SOURCE Lumen Technologies

Posted on

Halozyme Raises Full Year 2020 Guidance

– Raises 2020 Guidance to $265 Million to $275 Million in Revenues, Up from $250 Million to $260 Million, and EPS of $0.90 to $0.95, Up from $0.80 to $0.85 –

PR Newswire

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc.

The Company is raising full year 2020 revenue guidance to $265 million to $275 million to reflect incremental anticipated revenues as Halozyme and its partners continue to execute on a number of fourth quarter revenue-related activities.

The Company now expects:

  • Revenues of $265 million to $275 million, increased from prior guidance of $250 million to $260 million, representing growth of 35% to 40% over prior year revenues;
  • Earnings per share on a GAAP basis of $0.90 to $0.95, increased from prior guidance of $0.80 to $0.85.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients’ lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme’s commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme’s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company’s partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company’s financial outlook for 2020) and expectations for future growth, profitability, revenue, expenses and earnings-per-share. Forward-looking statements regarding the Company’s ENHANZE®  business may include potential growth driven by our partners’ development and commercialization efforts. These forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, unexpected results or delays in the growth of the Company’s ENHANZE® business, or in the development, regulatory review or commercialization of ENHANZE® products, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company’s most recently filed Annual Report on Form 10-Q filed with the Securities and Exchange Commission.

Contact:

Al Kildani

Vice President, Investor Relations and Corporate Communications
858-704-8122
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-raises-full-year-2020-guidance-301178597.html

SOURCE Halozyme Therapeutics, Inc.

Posted on

Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud

PR Newswire

The Tony Blair Institute for Global Change and Oracle partner with African governments to manage large-scale vaccination programs in the cloud – over 73,000 people vaccinated
and registered in the
first 8 days in Ghana

LONDON and REDWOOD SHORES, Calif., Nov. 23, 2020 /PRNewswire/ — The Tony Blair Institute (TBI) and Oracle have brought cloud technology to Africa to manage public health programs. Initially, Ghana, Rwanda, and Sierra Leone will use the new Oracle Health Management System to create electronic health records for their vaccination programs for yellow fever, HPV, polio, measles, and COVID-19, as soon as that vaccine is distributed to Africa. TBI and Oracle are in discussions with more than thirty other countries in Africa, Asia, Europe, and North America that are evaluating using the same cloud system to manage their COVID-19 vaccination programs.  

 

“Since February of this year, the Africa Union and Member States have worked tirelessly together to address the impact of COVID-19 on the continent,” said Dr. John Nkengasong, Director of the Africa Centres for Disease Control and Prevention. “As the COVID-19 pandemic continues, partnerships such as this one with Oracle, TBI and various governments are critical to the strengthening of Member State public health institutions, not only to incorporate innovative technology but to proactively and urgently harmonize the collection and sharing of important testing data across the continent.”

TBI has been providing policy advice and hands-on support to African governments as they tackle complex COVID-19 challenges. To address these challenges, TBI partnered with Oracle to deliver cloud technology to digitize and unify national health data starting with the management of vaccinations. The Oracle Health Management System creates an electronic health record in a cloud database for every person as they are vaccinated. This highly-secure system can be quickly configured to interoperate with each country’s existing technology and meet their most stringent data sovereignty requirements. Participating countries will have access and support for the system, free of charge, for the next ten years.

“This is an immensely exciting and potentially ground-breaking initiative for recording information on all disease vaccinations and treatments in African nations,” said Tony Blair, Executive Chairman of TBI and the former Prime Minister of Great Britain and Northern Ireland. “Though Africa has coped well with COVID-19, it still needs to be part of international efforts to control the disease, including for international travel. That means vaccination of at least a significant portion of the population, requiring the highest quality data system so that everyone’s vaccine experience is recorded. Oracle can provide that system with data securely stored and owned by each country and is prepared to do so as part of a global philanthropic partnership.

We will be living with COVID-19 for some years, and the recording of data will be vital in managing its impact and spread. And one thing is clear from this crisis: applying new technology solutions has applications for the digitization of the entire economy and is crucial for the acceleration of African development. This initiative is a great test case, and my Institute is proud to be part of it.”  

“The Oracle Health Management System is currently being used by the U.S. government and large healthcare and research organizations to monitor COVID-19 patient symptoms, responses to treatments, and to screen volunteers for COVID-19 vaccine clinical trials,” said Oracle Chairman and CTO Larry Ellison. “By working with Tony and his team over a period of a few months, we were able to deliver the exact same 21st century cloud technology to Ghana, Rwanda, and Sierra Leone. This is the first time vaccine data has been stored in a cloud database on a national scale. Africa is leading the way.”

Bringing Cloud Technology for Electronic Health Records to Africa

Ghana is now using the system to manage its yellow fever vaccine program and will follow with COVID-19 once that vaccine is distributed in Africa.

Ghana President Nana Akufo-Addo said, “We have learned many lessons from this pandemic. The most obvious is that we have to urgently fortify our public health systems. This strategic partnership with Oracle and TBI is evidence of our drive to digitalize Ghana’s health systems for our people’s benefit.”

“The move from Ghana’s current paper-based vaccination campaign records to digital data management using the Oracle platform will enable our data to be easily accessible by authorized persons. The data will be more secure, and there will be no worry about lost cards as people travel,” added Dr. Kwame Amponsa-Achiano, Expanded Programme on Immunization, Ghana Health Service.

Hear more from Dr. Kwane Amponsa-Achiano at https://bit.ly/3fntnZf.

Rwanda has prepared its system to support its HPV vaccine administration as soon as secondary schools reopen, with plans to support COVID-19 vaccinations and an immunity pass for citizens in the future.

President of Rwanda, Paul Kagame called for a resilient health system as the best defense against future pandemics: “A COVID-19 vaccine will be a critical tool, and Africa must be able to access to its fair share of a vaccine once it is available. This partnership will deliver an innovative digital vaccine e-registry that signals the continent’s readiness to deploy the vaccine and to safely reopen our economies to trade and tourism.”

Sierra Leone is preparing to use the system to create digital vaccination records when its next routine Expanded Program on Immunization (EPI) campaign begins. EPI is a global initiative to vaccinate for polio, diphtheria, tuberculosis, pertussis, measles, and tetanus. It is estimated to prevent two to three million childhood deaths globally each year from these diseases. Sierra Leone’s EPI program reportedly covers 95% of eligible children in that country.

Chief Innovation Officer and Minister of Education of Sierra Leone, Dr. David Moinina Sengeh, noted, “The Government of Sierra Leone is committed to utilizing technology and innovation – digitizing services to improve service delivery for its citizens. Using our experience from Ebola, we were able to put together a robust National COVID-19 Response plan, which has technology, data, and innovation as core enablers. This collaboration with Oracle and TBI is significant not only for dealing with COVID-19 and broader health needs, such as EPI vaccinations but will be a key step in our country’s mission of digitization for all.”

As countries begin vaccinating people for COVID-19, the Oracle Health Management System can be used to automatically create an electronic health record for every person vaccinated.  Once the COVID-19 vaccine is available, the Oracle Health Management System will track immunizations and provide recipients with a Digital Quick Response (QR) code. These QR codes will help Africa reopen its borders and economies by providing citizens the proof of immunization needed to move freely for work and travel.

About the Tony Blair Institute for Global Change

TBI’s Government Advisory Practice directly supports leaders in their on-the-ground fight against COVID-19, and our Policy Futures unit is delivering analysis and advice to help countries mitigate economic impact, source essential equipment, harness the power of technology and position themselves for the rebuilding to come.

The tech revolution can be accelerated in Africa and other emerging and developing countries, not only to deal with COVID-19, but also embedding robust health care systems that will benefit citizens, and beyond health, to digitize public services and the economy.

About Oracle
Oracle offers suites of integrated applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/tony-blair-institute-and-oracle-launch-africa-vaccine-management-in-the-cloud-301178600.html

SOURCE Oracle

Posted on

TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the publication of clinical data that provides molecular insight into TRC102’s mechanism of action and patient populations most likely to respond to treatment. The article, entitled, “Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment,” highlights the clinical features and tumor biology of an exceptional responder patient treated with TRC102 at the National Cancer Institute (NCI): https://www.traconpharma.com/wp-content/uploads/2020/11/Can_Cell_2020_Nov_Mol_Analysis_ER.pdf

The patient was diagnosed with metastatic and highly refractory colorectal cancer and received temozolomide (Temodar®) and TRC102. Following treatment, the patient was considered an exceptional responder through the achievement of a near compete response lasting 45 months at the most recent follow-up. Detailed molecular analyses of the patient’s tumor showed silencing of DNA repair pathways that may have resulted in sensitivity to the inhibition of DNA base excision repair pathway by TRC102. Specifically, MGMT expression was silenced by promoter methylation, and RAD50, a mediator of DNA double strand break repair, was silenced by genetic mutation and loss of heterozygosity. The publication authors hypothesized that the combination of Temodar and TRC102 was effective because all necessary DNA repair pathways were compromised genetically or through the activity of TRC102. MGMT expression was also assessed in biopsies from 11 colorectal patients who subsequently enrolled in an expansion cohort, one of which demonstrated a partial response. The tumor associated with the partial response did not express MGMT, whereas each of the 10 tumors that did not respond to therapy expressed this enzyme robustly.

TRC102 is being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the NCI through a Cooperative Research and Development Agreement. TRC102 was also evaluated in a Phase 2 trial in combination with Temodar chemotherapy in 19 patients with progressive or recurrent glioblastoma who progressed following Temodar and external beam radiotherapy. Extended survival was observed in two patients for more than two years, both of whom demonstrated activation of the DNA base excision repair pathway and showed hyperactivation of DNA damage response genes prior to treatment with TRC102.

“The Cancer Cell publication supports our belief that patients whose cancers are dependent on the DNA base excision repair pathway to repair DNA damage from chemotherapy may be particularly sensitive to the pharmacologic effects of TRC102,” said James Freddo, M.D., Chief Medical Officer of TRACON. “The NCI data are also consistent with the results from the Phase 2 trial of Temodar and TRC102 in refractory glioblastoma. We remain committed to developing TRC102 in collaboration with the NCI and believe that the data generated to date provide strong rationale for studying TRC102 in combination with Temodar and radiotherapy in newly diagnosed patients with malignant glioma.”

About TRC102

TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute through a Cooperative Research and Development Agreement (CRADA). TRC102 was granted orphan drug designation by the US FDA for the treatment of malignant glioma in 2020. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical-trials.

About Malignant Glioma and GBM

GBM (also called glioblastoma) is a fast-growing malignant glioma that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. GBM is the most invasive type of glial tumors, rapidly growing and commonly spreading into nearby brain tissue. The National Cancer Institute estimates that approximately 22,850 adults (12,630 men and 10,280 women) are diagnosed with brain and other nervous system cancer annually in the U.S. and approximately 15,320 of these diagnoses will result in death. GBM has an incidence of two to three per 100,000 adults per year in the U.S., and accounts for 52 percent of all primary brain tumors.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma in a registrational trial in the U.S.; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate in development for the treatment of lung cancer and glioblastoma; and TJ004309, a Phase 1 CD73 antibody in development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.  To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON’s and the National Cancer Institute’s plans to further develop product candidates, expectations regarding clinical trials, development and regulatory plans, the potential benefits of TRC102, and TRACON’s business development strategy and goals. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development; whether TRACON or others will be able to complete or initiate clinical trials on TRACON’s expected timelines, if at all, including due to risks associated with the COVID-19 pandemic or other pandemics; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that TRACON has limited control over whether or when third party collaborators complete on-going trials, initiate additional trials or seek regulatory approval of TRACON’s product candidates; the fact that TRACON’s collaboration agreements are subject to early termination; whether TRACON will be able to enter into additional collaboration agreements on favorable terms or at all; potential changes in regulatory requirements in the United States and foreign countries; TRACON’s reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; whether TRACON will be able to obtain additional financing; and other risks described in TRACON’s filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Company Contact: Investor Contact:
Mark Wiggins Brian Ritchie
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 212-915-2578
[email protected]
[email protected]
   



Posted on

SJI Raises Dividend for 22nd Consecutive Year

FOLSOM, NJ, Nov. 23, 2020 (GLOBE NEWSWIRE) —                                                                                                 Media Contact:  609-561-9000 x4496
[email protected]

                                                                                                          Investor Contact: Dan Fidell
(609) 561-9000 ext. 7027
[email protected]

FOR IMMEDIATE RELEASE

SJI Raises Dividend for 22nd Consecutive Year

FOLSOM, NJ, November 23, 2020 – SJI (NYSE: SJI) announced today that its board of directors voted to increase the company’s regular quarterly dividend from $0.2950 per share to $0.3025 per share. The new annualized dividend of $1.21 represents an increase of 2.54 percent per share over the previous level.

With this announcement, SJI has increased its dividend for 22 consecutive years.

Factors the board of directors consider when setting the dividend include future earnings expectations, payout ratio and dividend yield relative to those at peer companies, as well as returns available on other income-oriented investments.  

The dividend is payable December 29, 2020 to shareholders of record at the close of business on December 10, 2020 with an ex-dividend date of December 9, 2020. This is SJI’s 69th consecutive year of paying dividends, reflecting the company’s commitment to a consistent, sustainable dividend.

About SJI

SJI (NYSE: SJI), an energy services holding company based in Folsom, NJ, delivers energy services to its customers through three primary subsidiaries. SJI Utilities, SJI’s regulated natural gas utility business, delivers safe, reliable, affordable natural gas to approximately 700,000 South Jersey Gas and Elizabethtown Gas customers in New Jersey. SJI’s non-utility businesses within South Jersey Energy Solutions promote efficiency, clean technology and renewable energy by providing customized wholesale commodity marketing and fuel management services; and developing, owning and operating on-site energy production facilities. SJI Midstream houses the company’s interest in the PennEast Pipeline Project. Visit sjindustries.com for more information about SJI and its subsidiaries. 

###



Posted on

GE Healthcare Announces First X-ray AI to Help Assess Endotracheal Tube Placement for COVID-19 Patients

GE Healthcare Announces First X-ray AI to Help Assess Endotracheal Tube Placement for COVID-19 Patients

  • Critical Care Suite 2.0 helps clinicians assess Endotracheal Tube (ETT) placement for intubated patients, including critical COVID-19 patients
  • New AI suite includes algorithms that help radiologists prioritize critical cases and automate processes to help cut average review time from up to eight hours1

WAUKESHA, Wis.–(BUSINESS WIRE)–
GE Healthcare today announced a new artificial intelligence (AI) algorithm to help clinicians assess Endotracheal Tube (ETT) placements, a necessary and important step when ventilating critically ill COVID-19 patients. The AI solution is one of five included in GE Healthcare’s Critical Care Suite 2.02, an industry-first collection of AI algorithms embedded on a mobile x-ray device for automated measurements, case prioritization and quality control.

Research shows that up to 25 percent3,4,5,6,7 of patients intubated outside of the operating room have misplaced ETTs on chest x-rays, which can lead to severe complications for patients, including hyperinflation, pneumothorax, cardiac arrest and death. Moreover, as COVID-19 cases climb, with more than 50 million confirmed worldwide8, anywhere from 5-15 percent require intensive care surveillance and intubation for ventilatory support9.

“Today, clinicians are overwhelmed, experiencing mounting pressure as a result of an ever-increasing number of patients,” said Jan Makela, President and CEO, Imaging at GE Healthcare. “The pandemic has proven what we already knew – that data, AI and connectivity are central to helping those on the front lines deliver intelligently efficient care. GE Healthcare is not only providing new tools to help hospital staff keep up with demand without compromising diagnostic precision, but also leading the way on COVID-era advancements that will have a long-lasting impact on the industry, long after the pandemic ends.”

Up to 45% of ICU patients, including severe COVID-19 cases, receive ETT intubation for ventilation10,11,12. While proper ETT placement can be difficult, Critical Care Suite 2.0 uses AI to automatically detect ETTs in chest x-ray images and provides an accurate and automated measurement of ETT positioning to clinicians within seconds of image acquisition, right on the monitor of the x-ray system. In 94% of cases the ET Tube tip-to-Carina distance calculation is accurate to within 1.0 cm13. With these measurements, clinicians can determine if the ETT is placed correctly or if additional attention is required for proper placement. The AI generated measurements – along with an image overlay – are then made accessible in a picture archiving and communication systems (PACS).

Improper positioning of the ETT during intubation can lead to various complications, including a pneumothorax, a type of collapsed lung. While the chest x-ray images of a suspected pneumothorax patient are often marked “STAT,” they can sit waiting for up to eight hours for a radiologist’s review14. However, when a patient is scanned on a device with Critical Care Suite 2.0,15 the system automatically analyzes images and sends an alert for cases with a suspected pneumothorax – along with the original chest x-ray – to the radiologist for review via PACS. The technologist also receives a subsequent on-device notification16 to provide awareness of the prioritized cases.

“Seconds and minutes matter when dealing with a collapsed lung or assessing endotracheal tube positioning in a critically ill patient,” explains Dr. Amit Gupta, Modality Director of Diagnostic Radiography at University Hospital Cleveland Medical Center and Assistant Professor of Radiology at Case Western Reserve University, Cleveland. “In several COVID-19 patient cases, the pneumothorax AI algorithm has proved prophetic – accurately identifying pneumothoraces/barotrauma in intubated COVID-19 patients, flagging them to radiologist and radiology residents, and enabling expedited patient treatment. Altogether, this technology is a game changer, helping us operate more efficiently as a practice, without compromising diagnostic precision. We soon will evaluate the new ETT placement AI algorithm, which we hope will be an equally valuable tool as we continue caring for critically ill COVID-19 patients.”

To make the AI suite more accessible, Critical Care Suite 2.0 is embedded on a mobile x-ray device – offering hospitals an opportunity to try AI without making investments into additional IT infrastructure, security assessments or cybersecurity precautions for routing images offsite.

Furthermore, the on-device AI offers several benefits to radiologists and technologists:

  • ETT positioning and critical findings: GE Healthcare’s algorithms are a fast and reliable way to ensure AI results are generated within seconds of image acquisition, without any dependency on connectivity or transfer speeds to produce the AI results.
  • Eliminating processing delays: Results are then sent to the radiologist while the device sends the original diagnostic image, ensuring no additional processing delay.
  • Ensuring quality: The AI suite also includes several quality-focused AI algorithms to analyze and flag protocol and field of view errors as well as auto rotate the images on-device. By automatically running these quality checks on-device, it integrates them into the technologist’s standard workflow and enables technologist actions – such as rejections or reprocessing – to occur at the patient’s bedside and before the images are sent to PACS.

GE Healthcare and UC San Francisco co-developed Critical Care Suite 2.0 using GE Healthcare’s Edison platform, which helps deploy AI algorithms quickly and securely. Critical Care Suite 2.0 is available on the company’s AMX 240 mobile x-ray system.

For more information on GE Healthcare and Critical Care Suite 2.0 visit the company’s virtual RSNA booth or gehealthcare.com. Clinicians can also test the Critical Care Suite 2.0 algorithms by uploading their own chest x-ray images to gexray.ai.

About GE Healthcare:

GE Healthcare is the $16.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

1 Rachh, Pratik et al. “Reducing STAT Portable Chest Radiograph Turnaround Times: A Pilot Study.” Current Problems in Diagnostic Radiology Vol. 47, No. 3 (n.d.): 156–60. https://www.sciencedirect.com/science/article/abs/pii/S0363018817300312?via=ihub.

2 Critical Care Suite 2.0 is only available in the United States. Not cleared or approved by the FDA. Distributed in accordance with FDA imaging guidance regarding COVID-19 public health emergency.

3 Jemmett ME, Kendal KM, Fourre MW, Burton JH. Unrecognized misplacement of endotracheal tubes in a mixed urban to rural emergency medical services setting. Acad Emerg Med 2003;10:961–5.

4 Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. Ann Emerg Med 2001;37:32–7.

5 Lotano R, Gerber D, Aseron C, Santarelli R, Pratter M. Utility of postintubation chest radiographs in the intensive care unit. Crit Care 2000;4:50–3.

6 McGillicuddy DC, Babineau MR, Fisher J, Ban K, Sanchez LD.

7 Is a postintubation chest radiograph necessary in the emergency department? Int J Emerg Med 2009;2:247–9.

8 WHO Coronavirus Disease (COVID-19) Dashboard. Published June 17, 2020. Retrieved November 10, 2020, from https://covid19.who.int/.

9 Möhlenkamp S, Thiele H. “Ventilation of COVID-19 patients in intensive care units.” Nature Public Health Emergency Collection. 2020 Apr 20 :1–3

10 Hannah Wunsch, Jason Wagner, Maximilian Herlim, David Chong, Andrew Kramer, and Scott D. Halpern. ICU Occupancy and mechanical ventilator use in the United States. Crit Care Med. 2013 Dec; 41(12): 10.1097/CCM.0b013e318298a139.

11 Dawei Wang, Bo Hu, Chang Hu, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585

12 Lingzhong Meng, M.D.; Haibo Qiu, M.D.; Li Wan, M.D.; Yuhang Ai, M.D.; Zhanggang Xue, M.D.; et al. Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan’s Experience. Anesthesiology 6 2020, Vol.132, 1317-1332.

13 GE Healthcare data on file.

14 Rachh, Pratik et al. “Reducing STAT Portable Chest Radiograph Turnaround Times: A Pilot Study.” Current Problems in Diagnostic Radiology Vol. 47, No. 3 (n.d.): 156–60. https://www.sciencedirect.com/science/article/abs/pii/S0363018817300312?via=ihub.

15 Algorithm also available with GE Healthcare’s Critical Care Suite

16 The technologist on-device notification is generated after a delay, post exam closure, and it does not provide any diagnostic information, nor is it intended to inform any clinical decision, prioritization, or action.

Kate Rodgers

[email protected]

+1 262 202-5430

KEYWORDS: Wisconsin Illinois United States North America

INDUSTRY KEYWORDS: Technology Medical Devices Infectious Diseases Other Technology Software Biotechnology Radiology Health Data Management

MEDIA:

Logo
Logo
Posted on

ViewRay to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire

CLEVELAND, Nov. 23, 2020 /PRNewswire/ — ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

From November 23 to December 3, 2020, a fireside chat recording will be available for registered attendees via the Piper Sandler conference site. A recording will also be posted to the Company’s website at https://investors.viewray.com/events-and-presentations/upcoming-events.

ViewRay will be participating in investor meetings on Tuesday, December 1st, which can be requested exclusively via Piper Sandler.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viewray-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301178411.html

SOURCE ViewRay, Inc.

Posted on

Amyris To Present at Evercore ISI’s 3rd Annual HealthCONx Conference on December 3, 2020

PR Newswire

EMERYVILLE, Calif., Nov. 23, 2020 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that management will present at Evercore ISI’s 3rd Annual HealthCONx Conference on Thursday, December 3rd at 2:40 p.m. ET.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the company’s website at  http://investors.amyris.com.  

About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world’s top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands – all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and Purecane are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Cision View original content:http://www.prnewswire.com/news-releases/amyris-to-present-at-evercore-isis-3rd-annual-healthconx-conference-on-december-3-2020-301178651.html

SOURCE Amyris, Inc.

Posted on

Luokung Closed the Acquisition of BotBrain

PR Newswire

BEIJING, Nov. 23, 2020 /PRNewswire/ — Luokung Technology Corp. (NASDAQ: LKCO) (“Luokung” or the “Company”), one of the global leading spatial-temporal big-data processing technology companies, a leading interactive location-based services company in China, today announced it has closed the acquisition of 67.36% of BOTBRAIN AI LIMITED(“BotBrain”). The Company invested RMB 20 million to BotBrain and issued 1,789,618 to the former institution investors of BotBrain.

BotBrain has its unique technical advantages in AI subdomains such as Natural Language Processing (“NLP”), and it’s been actively using in knowledge management and knowledge services including knowledge graph construction, entity recognition, and personalized knowledge content interactions. BotBrain’s major clients including State Grid, China Mobile, FAW-Volkswagen, Bank of China, Tencent etc.

Luokung has been actively supporting BotBrain to increase its technical investment in NLP. At the same time, BotBrain’s technical capabilities in NLP and knowledge management will strongly support the construction of Luokung’s intelligent geographic knowledge system and provide Luokung customers with intelligent GIS and intelligent spatiotemporal data services.

In 2021, BotBrain’s intelligent knowledge management and service business is expected to contribute US$20 million in revenue to Luokung.

About Luokung Technology Corp.

Luokung Technology Corp. is one of the global leading spatial-temporal big-data processing technology companies and a leading interactive location-based services company in China. It provides integrated DaaS, SaaS, and PaaS services for Internet and Internet of Things of Spatial-Temporal big data based on its patented technology. Based on geographic information systems and intelligent Spatial-Temporal big data, it establishes city-level and industry-level digital twin holographic data models to actively serve smart cities, intelligent transportation, smart industry, LBS. http://www.luokung.com

Business Risks and Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

CONTACT:

The Company:
Mr. Jay Yu 
Chief Financial Officer
Tel:  +86-10-5327-4727
Email: [email protected]

INVESTOR RELATIONS
PureRock Communications Limited
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/luokung-closed-the-acquisition-of-botbrain-301178788.html

SOURCE Luokung Technology Corp.